A 2.5-year-old 62.6-kg (137.7-lb) pregnant female Huacaya alpaca was evaluated because of a mass associated with its left shoulder region. The mass was first detected 1 month prior and had doubled in size in the intervening period. The owners had not noted it to cause signs of pain, cause lameness, or affect the alpaca's eating or locomotion. There was no known traumatic event preceding the appearance of the mass. No other animals on the farm had similar lesions currently or in the past. The alpaca was reported to be in its 10th month of gestation, as determined on the
Objective—To determine uroplakin III expression, potential etiologic factors, biological behavior, and treatment response of transitional cell carcinoma (TCC) in the abdominal wall (ABWTCC) in dogs.
Design—Retrospective case series.
Animals—24 dogs with TCC of the urinary tract that also had histopathologic confirmation of ABWTCC.
Procedures—Medical records, histologic slides, radiographs, and ultrasonographic images of dogs with ABWTCC between July 1, 1985, and December 31, 2010, were reviewed. In available tissue specimens, immunohistochemistry was used to detect uroplakin III expression in the ABWTCC and in the primary tumor.
Results—The ABWTCC lesions ranged from < 2 to > 20 cm in diameter. Uroplakin III was expressed in 19 of 20 primary tumors and 17 of 17 ABWTCCs. Transitional cell carcinoma in the abdominal wall developed significantly more often in dogs that had undergone cystotomy (18/177 [10.2%]) than in those that had not (6/367 [1.6%]). In 1 dog that had not undergone cystotomy, TCC had invaded through the urinary bladder wall and spread down the median ligament to the abdominal wall. None of 18 dogs that received anticancer drugs had remission of the ABWTCC once clinically detected; median survival time after ABWTCC detection was 57 days (range, 0 to 324 days).
Conclusions and Clinical Relevance—Results suggested that ABWTCC is uncommon, but once TCC becomes established and clinically detectable in the abdominal wall, it carries a poor prognosis. It is crucial to minimize risk of TCC seeding at surgery. Percutaneous sampling of TCC should be avoided. Uroplakin III is commonly expressed in ABWTCC.
Objective—To assess the diagnostic utility of transurethral cystoscopic biopsy in dogs with histologically confirmed transitional cell carcinoma (TCC) of the urinary bladder and urethra.
Design—Retrospective case series.
Animals—92 dogs with histologically confirmed TCC.
Procedures—Information on sex, breed, neuter status, body weight, tumor location, biopsy method, number of biopsy procedures, experience level of clinician performing biopsy, and quality of biopsy sample was obtained from medical records. The association of variables with likelihood of achieving a diagnostic-quality biopsy sample was evaluated by use of logistic regression.
Results—If used as the initial biopsy method, cystoscopic biopsy samples were of diagnostic quality in 65% of male dogs and 96% of female dogs with histologically confirmed TCC. Cystoscopic biopsy samples were significantly more likely to be of diagnostic quality in female dogs than in male dogs.
Conclusions and Clinical Relevance—Cystoscopic biopsy is an effective method to obtain biopsy samples in dogs with TCC of the bladder and urethra. Cystoscopy is more likely to produce a diagnostic-quality biopsy sample in female dogs with TCC than in male dogs with TCC. Cystoscopy should be considered as a primary means of biopsy in male and female dogs with masses of the urinary bladder or urethra.
Objective—To evaluate the clinical and pathologic
characteristics of mammary duct ectasia in dogs.
Animals—51 dogs with mammary duct ectasia.
Procedure—Information regarding body condition,
history, number and location of affected mammary
glands, appearance of lesions, surgical treatment,
nonsurgical treatment, and evidence of recurrence or
development of mammary neoplasia was obtained
from surveys sent to referring veterinarians. Results
of information from examination of histologic sections
and referring veterinarians were evaluated for all
mammary duct ectasia biopsies performed between
1992 and 1999.
Results—Duct ectasia was the primary diagnosis in
51 of 1,825 (2.8%) mammary biopsy specimens and
comprised 48% of nonneoplastic mammary diseases.
Affected dogs were evenly distributed over a range of
1 to 13 years of age, with a mean age at the time of
diagnosis of 6.1 ± 3.1 years. All dogs were female (31
sexually intact, 20 spayed); 10 of 26 had whelped.
Duct ectasia was described as nodular (26 dogs), cystic
(13), and multiglandular (11) and located in caudal
(31) more often than cranial (14) or middle glands (10).
Ectasia recurred in 3 dogs. One dog had a history of
previously excised mammary adenocarcinoma; another
subsequently developed mammary carcinoma.
Conclusions and Clinical Relevance—Duct ectasia
affected mature, sexually intact and spayed female
dogs over a wide age range. Certain breeds were
affected more commonly than expected. Increased
risk for mammary neoplasia was not evident. Duct
ectasia should be considered as a cause for mammary
enlargement, especially in young dogs or when its
cystic nature is evident. Mastectomy is usually curative,
and neoplasia should be ruled out in dogs with
ectasia. (J Am Vet Med Assoc 2001;218:1303–1307)